XimeVT

[Mostafa Faisal @MostafaFaisal14]

🧬 AML study (2010–2024, n=187):
1️⃣ TDT groups: 1–5d (70%), 6–10d (16%), 11+d (14%)
2️⃣ CR ↓ with 11+d delay (OR=0.32, p=0.003)
3️⃣ No OS difference on multivariate analysis
📌 Waiting for full profiling before induction is safe

[Dr. Chokri Ben Lamine @abouabdrahman0]

🚨 AML 1st-line Tx Algorithm (ASCO 2025)

🔹 Assess: age, comorbidities, PS, chemo/radiotx exposure
🔹 Profile: morphology, immunophenotype, cytogenetics, molecular
👩‍⚕️ Eligible for intensive chemo

CBF-AML ➝ chemo ➕ gemtuzumab

FLT3 mut ➝ chemo ➕ FLT3i

t-AML / AML-MRC ➝ CPX-351

Others ➝ 7+3, FLAG-Ida

👩‍⚕️ Ineligible for intensive chemo

FLT3 mut ➝ FLT3i ➕ HMA/venetoclax

IDH1/2 mut ➝ IDH1/2i ± HMA

Others ➝ HMA ➕ venetoclax / LDAC ± glasdegib

🧬 Post remission

Based on ELN risk (Favorable 💚, Intermediate 💛, Adverse ❤️)

Transplant eligible ➝ allo-SCT

Transplant ineligible ➝ consolidation ± maintenance (CC-486)

✅ FDA approved 🔶 Not FDA approved

#AML #Leukemia #ASCO2025 #Hematology
Source: ASCO 2025

[Oncology Brothers @OncBrothers]

Treatment Algorithm: This is the algorithm we have used during our discussion with @KuykendallMd on Polycythemia Vera and Essential Thrombocythemia!

#OncTwitter #MedTwitter #HemeTwitter @OncUpdates

[Vincent Alcazer @AlcazerVincent]

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management
https://t.co/bbF7fJ8Be7

[Minoru Kanaya, 金谷穣 @MinoruKanaya]

Excited to share our latest article published in Blood Cancer Journal @BloodCancerJnl from Hokkaido Leukemia Net regarding duration of Venetoclax in AZA-VEN for AML patient. https://t.co/u4Rca2cJ7O

[GLAM @GlamSMD]

Este 11 de marzo nos juntamos para hablar de SMD de alto riesgo y las opciones terapéuticas para pacientes refractarios y recaídos con el Dr. Adolfo de la Fuente @MDAndersonNews @claramattosenri @VtXime #SMD #ALTORIESGO. No dejes de participar!

[GLAM @GlamSMD]

Gracias a todos los que participaron presencial y virtualmente #ASH2024 #latam @madicamp @garciamanero @VtXime @XimeJordan @ovilla_roberto @claramattosenri @marce_ebner

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

Very impressive overview of European and international cooperative clinical trials in #MDSsm at #ESHMDS2024 @ESHaematology in #EMSCO with a great panel discussion by top leaders in the field

[Camila Peña @CamiPenaO]

👀👀
Nuestro Diploma Hematología para médicos no especialistas... con mucho cariño y esfuerzo.

Más info👇

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

So satisfying to watch live the #ODAC meeting (at 4 AM Kyoto 🇯🇵 time where I am at #MDSsm meeting) & see vast majority of panel recognize the benefits over risks of #imetelstat based on our pivotal #IMerge trial, & look forward to having the drug approved for our patients!

[AmericanJournalofHematology @AjHematology]

New drugs in myelofibrosis

https://t.co/AxTFG1CAnw

[Camila Peña @CamiPenaO]

Diplomado "Hematología para médicos no especialistas"
👀👀❤️❤️
@hsalvadorcl @SALUDORIENTE
@MedichiUchile
https://t.co/fikAs9jDLn

[GLAM @GlamSMD]

Es hoy!!!! No te lo pierdas @visalinaspy @GrilleSofia @marce_ebner @VtXime @claramattosenri

[Talha Badar @TalhaBadarMD]

Weekend review 📖

What is the right duration of VENETOCLAX with HMA for AML: 7 days vs 14 days vs 21 days or 28 days?

Brief review of literature in this 🧵

#leusm #AML

[Blood Journals Portfolio @BloodPortfolio]

Causes and consequences of clonal hematopoiesis
https://t.co/NcTcUVCel3 #hematopoiesisandstemcells #myeloidneoplasia #reviewarticles #reviewseries

[Benlazar S M A @smbenlazar]

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with #CMML Treated with Hypomethylating Agents (HMA) https://t.co/iavGTCK0hn #ASH23

[Benlazar S M A @smbenlazar]

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival https://t.co/1jBo4zz6h7 #ASH23

[Benlazar S M A @smbenlazar]

How I treat transplant-eligible patients with myelofibrosis https://t.co/9wfHzim4mL #mpnsm

[Thomas Cluzeau @thomas_cluzeau]

Newsletter des essais clinique en #hematologie @CHUdeNice @ARSPaca #innovation #LAM #LAL #myelome #lymphome #SMD #SMP #LMC